Title: |
|
Pre-COVID-19 Retail Use and Expenditures for Drugs That Were Subsequently Used to Treat COVID-19 |
Description: |
|
The coronavirus pandemic is placing unprecedented strains on our health care system, including novel uses of medications to treat people with COVID-19. New uses may cause shortages, or price increases, that affect people who were using these drugs prior to the pandemic. The Medical Expenditure Panel Survey Household Component (MEPS-HC) provides an important national resource for understanding pre-COVID-19 retail and mail-order prescription drug use and expenditures. We identified a list of COVID-19-relevant drugs from published sources. For each COVID-19-relevant drug, we present estimates of average annual total users, total fills, total expenditures, fills per user, and expenditures per user. We also report the average annual percentage of the population who obtained these drugs overall and by users' sociodemographic and health characteristics, including age, sex, race, Census region, insurance status, poverty status and health status. We use this information to present the percent distribution of conditions associated with drugs that were subsequently used to treat COVID-19. |
Author(s): |
|
Yao Ding, PhD, G. Edward Miller, PhD, and Steven C. Hill, PhD |
Agency: |
|
Rockville (MD): Agency for Healthcare Research and Quality |
Back
Email Updates
